Outlook Therapeutics

CompanyUnited StatesFounded 2015

Outlook Therapeutics develops one asset, in phase 3 (ONS-5010 in age-related macular degeneration). Based in the United States, founded in 2015.

1
Asset
Furthest stage
Phase 3
Raised
$140M
5
Trials
0
Signals

Pipeline

1
  • ONS-5010

    Phase 3, age-related macular degeneration, neovascular age-related macular degeneration

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials5
  • Funding rounds and grants5
  • Deals14
  • People8
  • Signals3
  • Similar companies6

Intelligence